Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06657924 · ClinicalTrials.gov registry record · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
A Phase 2 study of Bleeding and Thromboembolism, sponsored by Kristen Ban.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 394
- Enrollment target
- 1
- Study location
NCT06657924 is a Phase 2 study of Bleeding and Thromboembolism that is actively recruiting participants, run by Kristen Ban. The registered enrollment target is 394 participants, below the 1,468-participant average among 23 other Bleeding trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06657924, a Phase 2 study of Bleeding and Thromboembolism, is actively recruiting participants, sponsored by Kristen Ban.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 394 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this prospective pragmatic randomized clinical trial is to determine if preoperative administration of tranexamic acid (TXA) reduces bleeding during and after major colorectal surgery. The primary questions are: * Does TXA reduce bleeding during and after surgery (change in hemoglobin from before surgery to lowest value after surgery within 30 days) * Does TXA reduce bleeding complications within 30 days of surgery (blood transfusion, return to the operating room or procedural intervention for bleeding, death due to bleeding) * Does TXA increase the risk of thromboembolic complications within 30 days of surgery (cerebrovascular accident, myocardial infarction, deep venous thrombosis, pulmonary embolism) Researchers will compare preoperative TXA to no TXA to answer the above questions. Participants who receive TXA will receive 1 g TXA IV at the beginning and end of surgery in the operating room.
Conditions Studied
Interventions
- DRUG Tranexamic acid
Study Locations (1)
Ohio
- Cleveland Clinic Fairview Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2025-02-11 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06657924
The ClinicalTrials.gov registry entry for NCT06657924 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,468-participant average among 23 other Bleeding trials with a reported enrollment target (73% lower). The listed sponsor is Kristen Ban, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic acid is the first listed.
NCT06657924 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06657924 about?
NCT06657924 is a clinical study titled "Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery". The goal of this prospective pragmatic randomized clinical trial is to determine if preoperative administration of tranexamic acid (TXA) reduces bleeding during and after major colorectal surgery. The primary questions are: * Does TXA reduce bleeding during and after surgery (change in hemoglobin f...
What is the current status of trial NCT06657924?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 394 participants. The study started on 2025-02-11. Estimated completion is 2026-10-01.
What conditions does trial NCT06657924 study?
This clinical trial studies the following conditions: Bleeding, Thromboembolism, Colorectal Disorders, Tranexamic Acid.
What interventions are being tested in trial NCT06657924?
The interventions under investigation include: Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT06657924?
This trial is sponsored by Kristen Ban, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06657924 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery
RECRUITING · Phase 2
-
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
COMPLETED · Phase 2
-
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
RECRUITING
-
Quantra Point-of-Care Hemostasis Monitoring
RECRUITING · NA
-
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
RECRUITING · Phase 4
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.